Associated Papers
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Functional Analysis and Clinical Data Reclassify the DICER1 c.4206+1G>C Variant, Leading to Exon 22 Skipping, as Likely Pathogenic.
Walpole S et al.
Clinical Genetics, 2025
DICER1 mutations in Bethesda III/IV thyroid cytology samples: A multicenter observational study.
Karimkhan A et al.
Cancer Cytopathology, 2025
DICER1 in pediatric and adult cancer predisposition populations: Prevalence, phenotypes, and mosaicism.
Salvador L et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2025
Widening the spectrum of players affected by genetic changes in Wilms tumor relapse.
Ciceri S et al.
Iscience, 2024
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage.
Mancikova V et al.
Molecular Oncology, 2023
Highly Sensitive Detection Method of DICER1 Tumor Hotspot Mutations by Drop-off Droplet Digital PCR.
Vibert R et al.
Clinical Chemistry, 2022
A complex DICER1 syndrome phenotype associated with a germline pathogenic variant affecting the RNase IIIa domain of DICER1.
Pontén E et al.
Journal of Medical Genetics, 2022
A pan-cancer atlas of somatic mutations in miRNA biogenesis genes.
Galka-Marciniak P et al.
Nucleic Acids Research, 2021
Ten years of DICER1 mutations: Provenance, distribution, and associated phenotypes.
de Kock L et al.
Human Mutation, 2019
Cancer-associated mutations in DICER1 RNase IIIa and IIIb domains exert similar effects on miRNA biogenesis.
Vedanayagam J et al.
Nature Communications, 2019
The prevalence of germline DICER1 pathogenic variation in cancer populations.
Kim J et al.
Molecular Genetics & Genomic Medicine, 2019
Clinical and Molecular Characteristics May Alter Treatment Strategies of Thyroid Malignancies in DICER1 Syndrome.
van der Tuin K et al.
The Journal of Clinical Endocrinology and Metabolism, 2019
Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome: Histologic and Molecular Alterations.
Gullo I et al.
American Journal of Clinical Pathology, 2018
DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors.
de Kock L et al.
The American Journal of Surgical Pathology, 2017
The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors.
Wang Y et al.
Neoplasia (new York, N.y.), 2015
Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour.
Torrezan GT et al.
Nature Communications, 2014
Expanding the phenotype of mutations in DICER1: mosaic missense mutations in the RNase IIIb domain of DICER1 cause GLOW syndrome.
Klein S et al.
Journal of Medical Genetics, 2014
Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.
Heravi-Moussavi A et al.
The New England Journal of Medicine, 2012